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Background:The National Lung Screening Trial demonstrated that screening for lung can-
cer improved overall survival (OS) and reduced lung cancer mortality in the 55- to 74-year-old
age group by increasing the proportion of cancers detected at an early stage. Because of the
increasing life expectancy of the American population, we investigated whether screening
for lung cancer might benefit men and women aged 75–84 years.
Materials/Methods: Rates of non-small cell lung cancer (NSCLC) from 2000 to 2009 were
calculated in both younger and older age groups using the surveillance epidemiology and
end reporting database. OS and lung cancer-specific survival (LCSS) in patients with Stage
I NSCLC diagnosed from 2004 to 2009 were analyzed to determine the effects of age and
treatment.
Results:The per capita incidence of NSCLC decreased in the 55–74 cohort, but increased
in the 75–84 cohort over the study period. Crude lung cancer death rates in the two age
groups who had no specific treatment were 39.5 and 44.9%, respectively.These rates fell in
both age groups when increasingly aggressive treatment was used. Rates of OS and LCSS
improved significantly with increasingly aggressive treatment in the 75–84 age group. The
survival benefits of increasingly aggressive treatment in 75- to 84-year-old females did not
differ from their counterparts in the younger cohort.
Conclusion: Screening for lung cancer might be of benefit to individuals at increased risk
of lung cancer in the 75–84 age group. The survival benefits of aggressive therapy are
similar in females between 55–74 and 75–84 years old.
Keywords: lung cancer, elderly, screening, radiotherapy, thoracic surgery
INTRODUCTION
The results of the National Lung Screening Trial (NLST) were
reported in 2011 (1). This study randomized 53,454 patients who
had at least a 30-pack-year history of smoking, did not have a
previous history of lung cancer, and were between ages 55 and
74 years old to receive three annual low-dose computerized tomo-
grams (CT) or a single posteroanterior chest X-ray. Patients in
the CT arm had a 20% relative reduction in lung cancer-specific
mortality and a 6.7% reduction in the risk of death from any
cause. These reductions appear due to finding cancers at a much
earlier, more curable stage than otherwise expected (1, 2). How-
ever, this trial did not include individuals aged 75 years or older
(defined as “elderly”), yet more than half of all lung cancers in
North Americans occur in patients aged over 70 years (3, 4). The
elderly population in the United States is increasing rapidly. Life
expectancy has increased over time in all races, and the burden of
lung cancer remains substantial in the elderly (5). Women aged
75 years have an average life expectancy of 12.9 years, and men
have an average of 11.0 years (6).
We therefore chose to investigate whether screening might be
beneficial in the elderly population (75–84 years old) by determin-
ing the outcome for patients with Stage I non-small cell lung cancer
(NSCLC) in this age cohort and comparing it to that of patients
55–74 years old. Our findings suggest that individuals in both age
cohorts have similar outcomes when treated in the same fashion,
and therefore screening may be of benefit to elderly individuals
at increased risk of lung cancer who are fit enough to undergo
treatment.
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DATA AND METHODS
DATA SOURCE
Data for this study were taken from the surveillance epidemi-
ology and end results (SEER) program of the National Cancer
Institute (NCI), which started to collect and publish cancer inci-
dence and survival data from population-based cancer registries
in 1973. The “SEER-9” registries are Atlanta, Connecticut, Detroit,
Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget
Sound, and Utah. Data are available for cases diagnosed from
1973 and later for most of these registries. The “SEER-18” data-
base used in this study includes the above registries and those
in Los Angeles, San Jose-Monterey, Rural Georgia, Greater Cal-
ifornia, Kentucky, Louisiana, New Jersey, Greater Georgia, and
the Alaska Native Tumor Registry (7). Data are available from
all cases diagnosed from 2000 and later for these registries.
The SEER-18 sites cover approximately 28% of the American
population (8).
COHORT SELECTION
Since small cell lung cancer rarely presents at an early stage even
when screening is employed (1–2.2%) (9), we excluded patients
with this histology from our study. We included adults aged
55–84 years who were diagnosed with NSCLC in the SEER-18
data-base during 2004–2009. A total of 191,868 patients aged 55–
74 years and 94,828 patients aged 75–84 years met the eligibility
criteria. Since the data from the SEER registry are de-identified,
no IRB approval was requested.
Outcome was examined for the 14,007 patients with NSCLC
diagnosed during the years 2004–2009 for whom sufficient infor-
mation was collected to assess the outcome of treatment in relation
to patient and histopathologic variables. Patients included in this
investigation had NSCLC as their first primary cancer, tumor size
4 cm or smaller, clinical T1-2N0 disease, extension codes 100, 110,
or 300, and only one type of local treatment (e.g., patients receiving
both radiation and surgery were excluded).
OUTCOME VARIABLES AND OTHER COVARIATES
The outcome variables were overall survival (OS) and lung cancer-
specific survival (LCSS). Deaths from other causes were treated as
censoring events. The exploratory variable of main interest was
the type of treatment that patients received. Treatments were cat-
egorized as: observation only; radiation only; subtotal resection
(sub-lobar resection; segmental resection, including lingulectomy;
or wedge resection); and lobectomy or greater (lobectomy or bi-
lobectomy, with or without extension to include the chest wall;
lobectomy with mediastinal node dissection; extended lobectomy
or bi-lobectomy, not otherwise specified; pneumonectomy with
mediastinal node dissection; or pneumonectomy, not otherwise
specified).
Other variables (in addition to age cohort) examined for their
potential effect on outcome were: gender; year of diagnosis; marital
status; race; Hispanic origin; tumor size; histology; grade; location;
and extension. Median follow-up time was 26 and 21 months in
the 55- to 74- and 75- to 84-year-old age groups, respectively.
STATISTICAL ANALYSIS
The incidence rates of NSCLC per 100,000 individuals in the
SEER-18 population were calculated via SEERSTAT. T -tests were
performed to analyze if there was significant difference in inci-
dence rates by age group. Trend analyses were used to determine if
incidence rates exhibit an increasing or decreasing trend over time.
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FIGURE 1 | Incidence and proportions of non-small cell lung cancer, 2000–2009 in both genders, females and males.
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Table 1 | Patient characteristics by age groups (N =14,007).
55–74 75–84 p-Value
TREATMENT
Observation 612 (6.4) 541 (12.2) <0.0001
Radiation 903 (9.4) 829 (18.8)
Subtotal resection 1,621 (16.9) 818 (18.5)
Lobectomy 6,452 (67.3) 2,231 (50.5)
YEAR AT DIAGNOSIS
2004 1,476 (15.4) 659 (14.9) 0.6155
2005 1,468 (15.3) 689 (15.6)
2006 1,620 (16.9) 726 (16.4)
2007 1,661 (17.3) 735 (16.6)
2008 1,664 (17.4) 788 (17.8)
2009 1,699 (17.7) 822 (18.6)
MARITAL STATUS
Married 5,618 (58.6) 2,203 (49.9) <0.0001
Separated 91 (1.0) 16 (0.4)
Single (never married) 989 (10.3) 245 (5.5)
Widowed 1,315 (13.7) 1,482 (33.5)
Unknown 281 (2.9) 135 (3.1)
GENDER
Female 5,189 (54.1) 2,504 (56.7) 0.0049
Male 4,399 (45.9) 1,915 (43.3)
RACE
White 8,215 (85.7) 3,951 (89.4) <0.0001
American Indian/Alaska native 34 (0.4) 10 (0.2)
Asian or Pacific Islander 459 (4.8) 221 (5.0)
Black 848 (8.8) 227 (5.1)
Other unspecified (1991+) 7 (0.1) 4 (0.1)
Unknown 25 (0.3) 6 (0.1)
HISPANIC ORIGIN
Non-Spanish–Hispanic–Latino 9,209 (96.1) 4,241 (96.0) 0.8324
Spanish–Hispanic–Latino 379 (4.0) 178 (4.0)
HISTOLOGY
Squamous 2,411 (28.8) 1,295 (33.1) <0.0001
Adenocarcinoma-BAC 780 (9.3) 282 (7.2)
Large cell 310 (3.7) 139 (3.6)
Adenocarcinoma 3,956 (47.3) 1,651 (42.1)
Other NSCLC 177 (2.1) 78 (2.0)
NSCLC NOS 727 (8.7) 473 (12.1)
GRADE
Well-differentiated 1,537 (16.0) 677 (15.3) <0.0001
Moderately differentiated 3,648 (38.1) 1,563 (35.4)
Poorly differentiated 2,705 (28.2) 1,148 (26.0)
Undifferentiated; anaplastic 165 (1.7) 76 (1.7)
Unknown 1,532 (16.0) 955 (21.6)
LOCATION (%)
Left lower lobe 1,214 (12.7) 618 (14.0) 0.0545
Right lower lobe 1,565 (16.3) 743 (16.8)
Main bronchus 15 (0.2) 10 (0.2)
Left upper lobe 2,637 (27.5) 1,241 (28.1)
Middle Lobe 496 (5.2) 227 (5.1)
Overlapping lesions 41 (0.5) 21 (0.5)
Right upper lobe 3,434 (35.8) 1,460 (33.0)
(Continued)
55–74 75–84 p-Value
LOCATION (%)
Left, NOS 64 (0.7) 42 (1.0)
Right, NOS 71 (0.7) 40 (0.9)
NOS 51 (0.5) 17 (0.4)
Median tumor size, mm 19.1 (6.5) 20.5 (6.3) <0.0001
Values are N (%) or median (standard error).
Chi-square tests and t-tests.
Some values missing.
Chow tests were used to determine whether the slopes in two linear
trend lines of incidence rates were equal by age group (10).
Chi-square and t -test were used to compare difference between
the two age cohorts with respect to treatment, patient characteris-
tics, and tumor characteristics. OS and LCSS were calculated using
Kaplan–Meier estimation (11). The statistical significance of dif-
ferences between these rates was calculated using the log-rank test.
Cox proportional hazards model estimates (12) were used to show
how treatment and other covariates were related to outcome. The
older cohort was divided into two age groups in the multivariate
analyses (aged 75–79 and 80–84 years). The hazards ratio (HR)
for treatments and their corresponding p-values were estimated
from the regression coefficient, and the standard error from the
proportional hazards models.
To better understand the relationship of treatment and survival
between the age cohorts, we included an interaction effect between
treatment and age group in proportional hazards models. All mul-
tivariate analyses were conducted using SAS software version 9.2,
and all statistical tests assumed a two-tailed α= 0.05.
RESULTS
The annual incidence rates per 100,000 persons for NSCLC were
significantly higher in the 75–84-year-old age group than in
the younger age group (Figure 1). Of note, the annual inci-
dence rates increased over time for the older female age cohort
(p= 0.0017) while staying stable for older males and younger
females and decreasing for younger males (p= 0.0065). The Chow
tests revealed significant difference in the slopes of trend lines
(p= 0.0017), especially for women (p= 0.0011). The proportion
of NSCLC cases fell in the 55–74 group and increased in the 75–
84 group during the study period for all stages as well as Stage I
tumors ≤4 cm (data not shown).
Characteristics of the 14,007 patients who met our study’s eli-
gibility criteria for outcome analysis (9,588 in the younger and
4,419 in the older cohorts) are listed in Table 1. The study cohort
was evenly distributed during 2004–2009, and the yearly distri-
butions were not significantly different in the two age groups.
The proportion of widowed patients in the younger group was
substantially lower than in the older group (13.7 vs. 33.5%;
p< 0.0001); 54.1% of patients in the younger group were female,
which was lower than the older group (56.7%, p= 0.0049); and
85.7% of patients in the younger group were white, lower than
in the older group (89.4%, p< 0.0001). Approximately 96% of
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Table 2 |Top three causes of death and 5-year overall survival rates in patients with stage I non-small cell lung cancer, 2004–2009.
55–74 Age group 75–84 Age group
Observation Radiation Subtotal
resection
Lobectomy Observation Radiation Subtotal
resection
Lobectomy
Sample N 612 903 1,621 6,452 541 829 818 2,231
Alive % 40.0 54.3 77.9 84.1 33.8 53.4 68.3 74.7
Death from lung cancer % 39.5 30.0 13.0 9.0 44.9 31.1 16.0 13.2
Diseases of heart % 4.7 2.8 1.4 1.7 5.2 4.3 5.1 2.8
Chronic obstructive pulmonary
disease and allied cond %
5.1 5.2 2.2 1.1 3.7 4.0 3.2 1.8
SAMPLE N
Male 299 421 748 2,931 234 342 359 980
Female 313 482 873 3,521 307 487 459 1,251
DIED OF LUNG CANCER
Male % 43.5 32.8 13.8 10.5 43.2 30.7 19.5 16.0
Female % 35.8 27.6 12.3 7.7 46.3 31.4 13.3 11.0
5-YEAR OVERALL SURVIVAL
Male % 10.5 22.4 59.2 69.6 8.8 13.0 34.2 50.8
Female % 25.0 28.7 61.7 75.7 10.9 19.8 57.9 64.2
patients were non-Hispanic, and the distributions of Hispanic
ethnicity were not significantly different in the two age groups.
There were fewer squamous cell carcinoma patients in the younger
group than in the older group (28.8 vs. 33.1%, p< 0.0001);
and 54.1% of the tumors in the younger group were well-
differentiated or moderately differentiated, higher than among
patients in the older group (50.7%, p< 0.0001). Approximately
28% of patients had cancer diagnosed in the left upper lobe, and
the distributions of location were not significantly different in
the two age groups. The average tumor size was 1.4 mm smaller
in the younger group than the older group (19.1 vs. 20.5 mm,
p< 0.0001). As expected, younger patients were more likely to
be treated with lobectomy or pneumonectomy (67.3 vs. 50.5%,
p< 0.0001).
Table 2 and Figure 2 show the proportion of NSCLC patients
who died (crude death rates) from lung cancer by treatment and
age group during 2004–2009. Lung cancer was the most com-
mon cause of death in all treatment groups in the younger age
cohort. Lung cancer was also the most common cause of death in
all treatment groups in the older cohort. Crude death rates from
lung cancer decreased in both age cohorts as the aggressiveness of
treatment increased.
Table 2 also shows that the 5-year OS rates improved signif-
icantly with increasingly aggressive treatment in both the 55–75
and 75–84-year age groups. The survival curves in Figure 3 again
revel that OS improved significantly with increasingly aggressive
treatment in the 75–84 group among both genders. The survival
curves in the older group for each treatment appear to be similar
to those for the younger group.
Adjusted risks of death were determined using standard multi-
variate Cox proportional hazards models, including year of diag-
nosis, marital status, race, Hispanic ethnicity, tumor size, tumor
grade, tumor location, histology, tumor extension, and treatment
covariates. Table 3 displays the predictors of OS and LCSS from
Observaon Radiaon Subtotal resecon Lobectomy
39.54
30.01
12.95
8.99
44.92
31.12
16.01
13.18
Both Genders
55-74 75-84
FIGURE 2 | Cause of death from lung cancer (crude) by treatment and
age group (%): 2004–2009.
the hazards models in males and females in three age groups
(the elderly group was split into 75- to 79- and 80- to 84-year
age groups). Similar to the younger cohort, the risk of death
due to any cause in the 75–79 and 80–84-year age group was
significantly higher in patients treated with subtotal resection,
radiation, or observation than for patients treated with lobectomy
or greater.
Multivariate analysis included an interaction effect between
treatment and age group showed that there are gender differ-
ences in how aggressive treatment affects outcome for patients
in different age cohorts (Table 4). For female patients, the sur-
vival benefits of aggressive therapy are similar between 55–74 and
75–84 year-old age groups. In contrast, the survival benefits of
aggressive therapy are different between the 55–74 group and the
75–84 group in male patients.
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Table 3 | Adjusted hazards ratios for survival among the elderly age
group: comparison between treatments.
Overall survival Lung cancer-specific
survival
55–74-YEAR AGE GROUPS
Male N =3,951 N =3,951
Observation 6.090 (<0.0001) 7.285 (<0.0001)
Radiation 3.781 (<0.0001) 4.652 (<0.0001)
Subtotal resection 1.387 (0.0003) 1.401 (0.0055)
Lobectomy (reference) 1.000 1.000
Female N =4,301 N =4,301
Observation 5.497 (<0.0001) 6.170 (<0.0001)
Radiation 3.487 (<0.0001) 3.838 (<0.0001)
Subtotal resection 1.697 (0.0271) 1.789 (<0.0001)
Lobectomy (reference) 1.000 1.000
75–79-YEAR AGE GROUPS
Male N =1,087 N =1,087
Observation 3.940 (<0.0001) 5.302 (<0.0001)
Radiation 2.008 (<0.0001) 2.665 (<0.0001)
Subtotal resection 1.325 (0.0451) 1.340 (0.1405)
Lobectomy (reference) 1.000 1.000
Female N =1,324 N =1,324
Observation 6.268 (<0.0001) 10.283 (<0.0001)
Radiation 2.862 (<0.0001) 3.962 (<0.0001)
Subtotal resection 1.420 (0.0221) 1.533 (0.0389)
Lobectomy (reference) 1.000 1.000
80–84-YEAR AGE GROUPS
Male N =631 N =631
Observation 3.862 (<0.0001) 3.955 (<0.0001)
Radiation 1.999 (0.0003) 2.261 (0.0011)
Subtotal resection 1.878 (0.0005) 1.672 (0.0424)
Lobectomy (reference) 1.000 1.000
Female N =827 N =827
Observation 4.459 (<0.0001) 5.874 (<0.0001)
Radiation 3.276 (<0.0001) 4.653 (<0.0001)
Subtotal resection 1.137 (0.5387) 1.090 (0.7816)
Lobectomy (reference) 1.000 1.000
Adjusted for year of diagnosis, marital status, race, Hispanic ethnicity, tumor size,
tumor grade, tumor location, histology, and tumor extension.
Causes of mortality and death rates within 90 days of treatment
are listed in Table 5. The mortality rates within the observation
arms exceeded those of the active treatment arms for both age
group categories.
DISCUSSION
After the NLST trial report appeared, an expert panel composed
of members of the National Comprehensive Cancer Network
(NCCN), American College of Chest Physicians, American Soci-
ety of Clinical Oncology, and American Cancer Society reviewed
the literature and endorsed screening in patients aged 55- to 74-
years who have a 30-pack-year history of smoking who continue to
smoke or quit smoking within the past 15 years (13). However, the
American Association for Thoracic Surgery recommended screen-
ing for smokers and former smokers with a 30-pack-year history
of smoking and long-term lung cancer survivors aged 55–79 years
(4). The NCCN has recommended screening according to risk cri-
teria starting at the age of 50, but did not recommend an upper age
limit (14). Elderly patients were not included in four prospective,
randomized trials investigating the role of low-dose CT screen-
ing (15–18). Although three trials included patients older than the
NLST [maximum age 75, 76, and 80 years, respectively (19–21)],
all are much smaller and have not reported an effect of CT screen-
ing on LCSS and OS. This is unfortunate, since the elderly make
up a rapidly increasing part of the population of the United States
and other industrialized countries, and their incidence rate of lung
cancer is higher than for younger age groups.
The role of aggressive treatment for lung cancer in elderly
patients has been controversial. Clearly some patients who might
be eligible for a screening program based on smoking history
will not receive either radiation or surgery because of refusal
or co-morbidities. Additionally, smoking-related co-morbidities
and quality of life worsen in the elderly smoking population
as compared to younger patients (22). However, in our investi-
gation, lung cancer remains the most common cause of death
for patients in this age group who develop this diagnosis, and
aggressive treatment seemed to benefit those who underwent it
(particularly for women). Moreover, lung cancer deaths remain
the most common cause of death despite the inclusion of only
Stage I tumors and without the exclusion of patients with mul-
tiple co-morbidities. Additionally, despite the broad spectrum of
treating physicians in SEER, the 90-day mortality remained low
(<6%) in all active treatment arms, suggesting appropriate candi-
date selection. Because the majority of patients receive a definitive
surgical procedure in the younger and older populations (84.2
and 69.0%, respectively), we assume that like past studies (23, 24),
those patients not selected for surgery most likely were medically
inoperable. It should be emphasized that even in this unselected
population, the majority of the elderly population with Stage I
NSCLC were able to receive surgery, the standard of care, with
relatively low rates of mortality (30- and 31- to 90-day mortali-
ties were 2.1 and 3.5% in the lobectomy group and 1.8 and 3.5%
in the sub-lobar resection group) during the post-operative time
period.
As a society, we must be concerned with the costs of screen-
ing as well as the radiation exposure in the patients undergo-
ing screening. Nevertheless, low-dose CT screening could also
be used to detect other smoking-related ailments such as coro-
nary artery disease, chronic pulmonary disease, and osteoporosis
(25) as well as other smoking-related cancers (26). Furthermore,
because radiographic signs associated with COPD (pulmonary
artery enlargement and percentage of lung with a density of
≤−950 Hounsfield units) (27, 28) are associated with acute COPD
and changes in FEV1, such changes could be used for evaluation
and treatment.
There are many limitations to the SEER database. It does not
include information concerning co-morbidities, past or present
cigarette use, type of radiotherapeutic treatment [stereotactic body
radiation therapy (SBRT) or conventional external beam], fam-
ily history of cancer, medications, chemotherapeutic treatments,
occupational exposures, symptoms of lung cancer, and recent
weight loss. Additionally, our patient population is predominantly
www.frontiersin.org March 2014 | Volume 4 | Article 37 | 5
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FIGURE 3 | Overall survival curves for patients by age groups.
Table 4 | Wald tests of the interaction effect between age group and treatment in Cox proportional hazards model.
N Wald
chi-square
Pr>Chi Sq
Overall survival, male, 55–74 vs. 75–79 5,038 17.3800 <0.0001
Lung cancer-specific survival, male, 55–74 vs. 75–79 5,038 6.6519 0.0839
Overall survival, male, 55–74 vs. 80–84 4,582 29.1234 <0.0001
Lung cancer-specific survival, male, 55–74 vs. 80–84 4,582 14.5713 0.0022
Overall survival, female, 55–74 vs. 75–79 5,625 6.4545 0.0915
Lung cancer-specific survival, female, 55–74 vs. 75–79 5,625 8.1917 0.0422
Overall survival, female, 55–74 vs. 80–84 5,128 7.6409 0.0540
Lung cancer-specific survival, female, 55–74 vs. 80–84 5,128 4.8190 0.1855
Adjusted for year of diagnosis, marital status, race, Hispanic ethnicity, tumor size, tumor grade, tumor location, histology, tumor extension, age group, and treatment.
Caucasian, therefore, our results may not pertain to other racial
groups. Nonetheless, we feel that the findings from our study are
provocative.
The success of any screening program depends upon the ability
to find early-stage disease and whether treatment of early-stage
disease is beneficial. Because lung cancer survival depends greatly
upon initial tumor stage (29) and only small improvements in
survival have been seen in the last several decades in advanced
disease (30), we feel that our study may help identify a population
who were not identified in the initial screening studies and who
may benefit from lung cancer screening. Although, screening may
result in unnecessary treatment for breast and prostate cancers,
our results show that even in Stage I tumors (4 cm or less in size)
almost 40% of patients in both the younger and older groups will
succumb to lung cancer if they do not receive radiation or surgery.
Additionally, despite the expected increase in smoking-related co-
morbidities with age (22), the majority of the elderly population
received surgical treatment and had an increase in survival as the
treatment became increasingly aggressive similar to the younger
patient group who would be eligible for screening. Furthermore,
Frontiers in Oncology | Radiation Oncology March 2014 | Volume 4 | Article 37 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Varlotto et al. Lung cancer screening in 75–84 year patients
Table 5 | Mortality rates and causes of mortality within 90 days of treatment.
55–74 Group 75–84 Group
Observation Radiation Sub-lobar Lobectomy Observation Radiation Sub-lobar Lobectomy
Initial patient # 612 903 1,621 6,452 541 829 818 2,231
% Mortality 30 days 8.5 0.8 1.3 1.0 9.6 1.7 1.8 2.1
% Mortality in 31–90 days 7.4 2.8 1.0 1.4 5.1 2.5 3.5 3.5
CAUSES OF MORTALITY IN FIRST 90 DAYSa
Lung cancer (%) 52 84 46 53 48 64 24 50
Heart disease (%) 14 11 12 17 12 26 10
COPD and related conditions (%) 9 6 7 6 17 9
Suicide and self-inflicted injury (%) 6
Unknown (%) 7 11 13 12 7 14
Pneumonia and influenza (%) 7 6
Other infectious diseases (%) 6
CVA (%) 5
aOnly causes of death exceeding 5.0% were listed for each treatment and age group category.
lung cancer is the most frequent cause of cancer death in both
genders (31).
It should be noted that our results demonstrate an increas-
ing incidence of lung cancer, and beneficial effects from aggressive
treatment in the 75- to 84-year-old age group, but they do not sug-
gest a screening population per se. Like the NLST, we eliminated
all patients with previous lung cancer and information concerning
co-morbidities was not available. Additionally, co-morbidity data
within large administrative databases depend upon the accuracy
of coding which has been noted to be subject to much variability
and underreporting in the past (32–34). However, differently than
the NLST, smoking history was not known. Therefore we could
not limit our analysis to patients with a 30-pack-year history of
smoking. Nevertheless, because greater than 85% of lung cancers
in the US are caused by cigarette smoking (35), the majority of
patients in our study were most likely current or past cigarette
smokers. Furthermore, even within the NLST, it appears the fur-
ther refinement of eligible patients would result in a more optimal
selection of candidates for screening. Sixty percent of patients at
highest risk for lung cancer death in 5 years accounted for 88%
of screening-prevented lung cancer deaths. These authors noted
similar results when assessing the benefits of screening according
to lung cancer incidence and that both the estimate of lung can-
cer death and incidence increased with age (36). Therefore, we
feel that prospective studies are needed to assess the most benefi-
cial populations to screen for lung cancer, but we do not feel that
patients should be discriminated against screening based upon age
alone.
We feel that the beneficial effects of treatment may have been
underestimated in our patient population. SEER-18 represents
approximately 28% of the US population regardless of physi-
cian expertise or hospital volume. Because lung cancer surgery
depends greatly upon both hospital (37) and physician volume
(38), the surgical outcomes may not be optimized. Additionally,
SBRT has higher control rates than conventional radiotherapy and
may offer an improvement in survival and control rates similar
to surgical resection (24, 39). However, as of 2007, only 1.1% of
the patients with Stage I NSCLC in the Medicare-SEER popu-
lation received SBRT as compared to 14.8% who received con-
ventional radiotherapy (40). Therefore, the full beneficial effects
of radiotherapy are probably under appreciated in our investiga-
tion. Moreover, SBRT can be easily administered to patients with
multiple co-morbidities and may result in fewer patients being
observed (39).
CONCLUSION
Because the rates of lung cancer are rising in the elderly and
because increasingly aggressive treatment is beneficial in these
patients, screening the 75- to 84-year-old age groups may be bene-
ficial. Furthermore, it should be noted that most of this unselected,
elderly population was able to undergo a definitive surgical resec-
tion. As recently shown in patients who were eligible for the NLST,
even in the 55- to 74-year-old age group, further refinement of
the at-risk patient populations is needed to find who would ben-
efit most from screening (33). We feel that patients 75 and older
should not be discriminated against lung cancer screening based
upon age alone.
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